Skip to content

Serotonin research published in 2022

Page 2 of 5: studies 21 to 40 of 86, newest first. Back to the serotonin overview

Studies

Neurovascular Uncoupling: Multimodal Imaging Delineates the Acute Effects of 3,4-Methylenedioxymethamphetamine

Journal of Nuclear Medicine September 29, 2022 Tudor M. Ionescu, Mario Amend, Tadashi Watabe et al. 19 citations

Psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA) have attracted increasing interest in recent years because of their therapeutic potential in psychiatric disorders. To understand the acute effects of psychedelic drugs in vivo, blood-oxygenation-level-dependent (BOLD) functional MRI (fMRI) has been widely used. In particular, fMRI studies have suggested that MDMA leads to...

DOI: 10.2967/jnumed.122.264391 (opens in new tab) Full text (opens in new tab) MDMA Serotonin transporter Hemodynamics Hallucinogen +4

Bespoke library docking for 5-HT2A receptor agonists with anti-depressant activity

Nature September 28, 2022 Anat Levit Kaplan, Danielle N. Confair, Kuglae Kim et al.

There is considerable interest in screening ultralarge chemical libraries for ligand discovery, both empirically and computationally 1 – 4 . Efforts have focused on readily synthesizable molecules, inevitably leaving many chemotypes unexplored. Here we investigate structure-based docking of a bespoke virtual library of tetrahydropyridines—a scaffold that is poorly sampled by a general...

Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice.

Neuroscience Letters September 25, 2022 Alaina M Jaster, Jason Younkin, Travis Cuddy et al. 53 citations

Psychedelics, also known as classical hallucinogens, affect processes related to perception, cognition and sensory processing mostly via the serotonin 5-HT2A receptor (5-HT2AR). This class of psychoactive substances, which includes lysergic acid diethylamide (LSD), psilocybin, mescaline and the substituted amphetamine 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), is receiving renewed...

DOI: 10.1016/j.neulet.2022.136836 (opens in new tab) Full text (opens in new tab) Classical hallucinogens Head-twitch behavior Psychedelics Serotonin 5-ht2a receptor +1

Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT2A Receptor Agonists.

Journal of Medicinal Chemistry September 22, 2022 Christian B M Poulie, Eline Pottie, Icaro A Simon et al. 32 citations

The serotonin 2A receptor (5-HT2AR) is the mediator of the psychedelic effects of serotonergic psychedelics, which have shown promising results in clinical studies for several neuropsychiatric indications. The 5-HT2AR is able to signal through the Gαq and β-arrestin effector proteins, but it is currently not known how the different signaling pathways contribute to the therapeutic effects...

DOI: 10.1021/acs.jmedchem.2c00702 (opens in new tab) Full text (opens in new tab) Psychedelic-medicine Pharmacology Mental-health Serotonin-research

Brain dynamics predictive of response to psilocybin for treatment-resistant depression

Research Square September 20, 2022 Jakub Vohryzek, Joana Cabral, Louis-David Lord et al. 10 citations preprint

Abstract Psilocybin therapy for depression has started to show promise, yet the underlying causal mechanisms are not currently known. Here we leveraged the differential outcome in responders and non-responders to psilocybin (10mg and 25mg, 7 days apart) therapy for depression - to gain new insights into regions and networks implicated in the restoration of healthy brain dynamics. We used...

Understanding the effects of serotonin in the brain through its role in the gastrointestinal tract.

Brain September 14, 2022 James M Shine, Claire O'Callaghan, Ishan C Walpola et al. 63 citations

The neuromodulatory arousal system imbues the nervous system with the flexibility and robustness required to facilitate adaptive behaviour. While there are well understood mechanisms linking dopamine, noradrenaline and acetylcholine to distinct behavioural states, similar conclusions have not been as readily available for serotonin. Fascinatingly, despite clear links between serotonergic...

Neural Mechanisms and Psychology of Psychedelic Ego Dissolution

Pharmacological Reviews September 9, 2022 Devon Stoliker, Adeel Razi, Gary F. Egan et al. 83 citations

Neuroimaging studies of psychedelics have advanced our understanding of hierarchical brain organization and the mechanisms underlying their subjective and therapeutic effects. The primary mechanism of action of classic psychedelics is binding to serotonergic 5-HT2A receptors. Agonist activity at these receptors leads to neuromodulatory changes in synaptic efficacy that can have a profound...

Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine–Assisted Therapy for Posttraumatic Stress Disorder

Journal of Clinical Psychopharmacology September 1, 2022 Collin M. Price, Allison A. Feduccia, Katrina Debonis

Abstract Background Among the renewed applications of psychedelic medicines in psychiatry, 3,4-methylenedioxymethamphetamine (MDMA)–assisted therapy for posttraumatic stress disorder (PTSD) has demonstrated the most promise in early small-scale studies. Recent exploratory analyses from prior clinical trials of MDMA-assisted therapy for PTSD have suggested that recent use of selective serotonin...

Motives for the use of serotonergic psychedelics: A systematic review.

Drug and Alcohol Review September 1, 2022 Lukas A Basedow, Sören Kuitunen-Paul 42 citations

Serotonergic psychedelics (SP) are psychoactive substances that produce unique sets of subjective effects, such as hallucinatory experiences. This systematic review is the first to summarise which motives for SP use have been assessed in medical, psychological, sociological and ethnological research across different types of SPs and across cultural backgrounds. Findings on use motives can be...

DOI: 10.1111/dar.13480 (opens in new tab) Full text (opens in new tab) Drug use Hallucinogens Motivation Reason +1

A Multidisciplinary Hypothesis about Serotonergic Psychedelics. Is it Possible that a Portion of Brain Serotonin Comes From the Gut?

Journal of Integrative Neuroscience August 31, 2022 Noémi Császár-nagy, Petr Bob, István Bókkon 9 citations

Here we present a complex hypothesis about the psychosomatic mechanism of serotonergic psychedelics. Serotonergic psychedelics affect gut microbes that produce a temporary increase of 5-HT by their host enterochromaffin cells (ECs). This increased 5-HT production—which is taken up and distributed by platelets—may work as a hormone-like regulatory signal that could influence membrane...

DOI: 10.31083/j.jin2105148 (opens in new tab) Serotonergic Serotonin Enterochromaffin cell Neurotransmission +6

Cerebrospinal Fluid Serotonin level as Biomarker for Neurotoxicity after 3,4-Methylenedioxymethamphetamine (MDMA)

Research Journal of Pharmacy and Technology August 30, 2022 Fatin H. Zakaria, Samhani Ismail, N.M.J Khadijah

A persistent 3,4-Methylenedioxymethamphetamine (MDMA) exposure may disrupt the human body serotonergic system which subsequently leads to physical and psychiatric chaos. Serotonin, a well-known monoamine neurotransmitter which is the main target of MDMA can be found in cerebrospinal (CSF) fluid. Its variation reflects the severity of neuronal damage caused by MDMA exposure. Hence, this article...

Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response

Biomedicine & Pharmacotherapy August 29, 2022 Ines Erkizia-Santamaría, R. Alles-Pascual, Igor Horrillo et al. 108 citations

The psychedelic 5-HT2A receptor (5HT2AR) agonist psilocybin (or the active metabolite psilocin) has emerged as potential useful drug for various neuropsychiatric diseases, with a rapid onset of therapeutic activity. However, the mechanisms responsible for such effects remain incompletely characterized. We aimed to study in vitro pharmacological profile and in vivo acute mechanism of...

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

Journal of Psychopharmacology August 26, 2022 Joost J. Breeksema, Bouwe Kuin, Jeanine Kamphuis et al. 171 citations

Introduction: Small-scale clinical studies with psychedelic drugs have shown promising results for the treatment of several mental disorders. Before psychedelics become registered medicines, it is important to know the full range of adverse events (AEs) for making balanced treatment decisions. Objective: To systematically review the presence of AEs during and after administration of...

The Association of Classic Serotonergic Psychedelic Use and Intention of Future Use with Nature Relatedness

Journal of Psychoactive Drugs August 19, 2022 Marcio S. C. Longo, Bheatrix Bienemann, Marco Multedo et al. 10 citations

This study sought to investigate the effects of different substances on nature relatedness (NR) in the general population. An online cross-sectional survey done in Brazil investigated use of ayahuasca/DMT, psilocybe mushrooms, LSD, MDMA/ecstasy, cocaine, cannabis, and alcohol. NR was assessed using the short-form version of the nature related scale (NR-6). One-way analysis of variance (ANOVA)...

The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder

The Canadian Journal of Psychiatry August 17, 2022 Joshua D. Rosenblat, Muhammad Ishrat Husain, Yena Lee et al. 58 citations

Objective Serotonergic psychedelics are re-emerging as potential novel treatments for several psychiatric disorders including major depressive disorder. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to review the evidence and provide a consensus recommendation for the clinical use of psychedelic treatments for major depressive disorder. Methods A systematic...

BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression

Journal of Integrative Neuroscience August 16, 2022 Ezio Carboni, Anna R. Carta 15 citations

Major depressive disorder is one of the primary causes of disability and disease worldwide. The therapy of depression is prevalently based on monoamine reuptake blockers; consequently, investigations aimed to clarify the aetiology of depression have mostly looked at brain areas innervated by monamines and brain circuitry involved in inputs and outputs of these areas. The recent approval of...

DOI: 10.31083/j.jin2105144 (opens in new tab) Serotonin Ventral tegmental area Stria terminalis Nucleus accumbens +8

Molecular insights into the regulation of constitutive activity by RNA editing of 5HT2C serotonin receptors

Cell Reports August 1, 2022 Ryan H. Gumpper, Jonathan F. Fay, Bryan L. Roth 49 citations

-transducer-coupled structures of three representative isoforms (INI, VGV, and VSV) with the selective drug lorcaserin (Belviq) and the classic psychedelic psilocin. We also provide a comprehensive analysis of agonist activation and constitutive activity across all 24 protein isoforms. Collectively, these findings reveal a unique hydrogen-bonding network located on intracellular loop 2 that is...

DOI: 10.1016/j.celrep.2022.111211 (opens in new tab) Rna editing Gene isoform G protein-coupled receptor Inverse agonist +3

Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice.

ACS Chemical Neuroscience July 28, 2022 Mario de la Fuente Revenga, Alaina M Jaster, John McGinn et al.

Classical psychedelics represent a subgroup of serotonergic psychoactive substances characterized by their distinct subjective effects on the human psyche. Another unique attribute of this drug class is that such effects become less apparent after repeated exposure within a short time span. The classification of psychedelics as a subgroup within the serotonergic drug family and the tolerance to...

A Dose of Creativity: An Integrative Review of the Effects of Serotonergic Psychedelics on Creativity

Journal of Psychoactive Drugs July 27, 2022 M. Costa

ABSTRACT This integrative review was conducted to summarize the knowledge pertaining to the effects that serotonergic psychedelics can have on creativity, a multi-dimensional construct referring to the ability to produce original and valuable artifacts. Psychedelics, which have long been hailed as substances that can enhance the creative process in their users, have experienced a recent...

Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses.

Neuroscience & Biobehavioral Reviews July 1, 2022 Drummond E-Wen Mcculloch, Gitte Moos Knudsen, Frederick Streeter Barrett et al. 14 citations

Clinical research into serotonergic psychedelics is expanding rapidly, showing promising efficacy across myriad disorders. Resting-state functional magnetic resonance imaging (rs-fMRI) is a commonly used strategy to identify psychedelic-induced changes in neural pathways in clinical and healthy populations. Here we, a large group of psychedelic imaging researchers, review the 42 research...